Pirfenidone News and Research

RSS
BIDMC, IPFnet to conduct clinical trials for idiopathic pulmonary fibrosis

BIDMC, IPFnet to conduct clinical trials for idiopathic pulmonary fibrosis

Cipla launches generic Pirfenidone for IPF

Cipla launches generic Pirfenidone for IPF

Roche receives development and commercialization rights for danoprevir drug

Roche receives development and commercialization rights for danoprevir drug

InterMune's development program for pirfenidone, IPF to be presented at Annual Congress of ERS

InterMune's development program for pirfenidone, IPF to be presented at Annual Congress of ERS

InterMune second-quarter total revenue decreases to $5.9 million

InterMune second-quarter total revenue decreases to $5.9 million

Data on Qnexa to be presented at World Congress on CODHy in Prague

Data on Qnexa to be presented at World Congress on CODHy in Prague

Stereotaxis to be featured prominently in 31st HRS

Stereotaxis to be featured prominently in 31st HRS

Graymark Healthcare first-quarter consolidated net revenues increase 7% to $27.6 million

Graymark Healthcare first-quarter consolidated net revenues increase 7% to $27.6 million

PAREXEL further expands presence in China with offices in Chengdu and Guangzhou

PAREXEL further expands presence in China with offices in Chengdu and Guangzhou

Solta Medical honored with Provectus Award at first annual Bright Lights Conference

Solta Medical honored with Provectus Award at first annual Bright Lights Conference

Amira Pharmaceuticals' LPA1 receptor antagonist program data published in British Journal of Pharmacology

Amira Pharmaceuticals' LPA1 receptor antagonist program data published in British Journal of Pharmacology

FDA's call for further review of pirfenidone disappointing for Pulmonary Fibrosis patients, says CPF

FDA's call for further review of pirfenidone disappointing for Pulmonary Fibrosis patients, says CPF

New findings show seaweed extract inhibits H1N1 virus

New findings show seaweed extract inhibits H1N1 virus

InterMune reports Phase 1b MAD study results of RTV-boosted danoprevir in HCV patients at 45th EASL

InterMune reports Phase 1b MAD study results of RTV-boosted danoprevir in HCV patients at 45th EASL

EMA validates InterMune's pirfenidone MAA for IPF

EMA validates InterMune's pirfenidone MAA for IPF

CPF, PFF applaud PF patients' efforts to plead with FDA Advisory Panel regarding lack of treatment options

CPF, PFF applaud PF patients' efforts to plead with FDA Advisory Panel regarding lack of treatment options

FDA's Advisory Committee votes 9-3 to recommend approval of Esbriet for treatment of patients with IPF

FDA's Advisory Committee votes 9-3 to recommend approval of Esbriet for treatment of patients with IPF

NASDAQ halts trading of InterMune's common stock, FDA PADAC to discuss pirfenidone NDA

NASDAQ halts trading of InterMune's common stock, FDA PADAC to discuss pirfenidone NDA

FDA's PADAC meeting to review pirfenidone NDA: InterMune posts briefing documents

FDA's PADAC meeting to review pirfenidone NDA: InterMune posts briefing documents

InterMune seeks European marketing approval for pirfenidone

InterMune seeks European marketing approval for pirfenidone

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.